Steph & CO Biomarin Pharmaceutical Inc Transaction History

Steph & CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 Apr 16, 2021	SELL	$74.73 - $90.69 $111,198 - $134,946	-1,488 Closed	0 $0
Q4 2020 Jan 29, 2021	BUY	$72.61 - $90.2 $3,267 - $4,059	45 Added 3.12%	1,488 $130,000
Q3 2020 Oct 27, 2020	BUY	$71.87 - $131.03 $8,911 - $16,247	124 Added 9.4%	1,443 $110,000
Q2 2020 Jul 15, 2020	SELL	$79.55 - $124.22 $42,320 - $66,085	-532 Reduced 28.74%	1,319 $163,000
Q1 2020 Apr 14, 2020	BUY	$71.37 - $96.85 $13,845 - $18,788	194 Added 11.71%	1,851 $156,000
Q4 2019 Feb 24, 2020	BUY	$64.27 - $86.37 $106,495 - $143,115	1,657 New	1,657 $140,000

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Steph & CO, based on Form 13F filings with the SEC.

Stay updated on Steph & CO with notifications on news.